Cross-neutralizing human monoclonal anti-HIV-1 antibody 2F5:: Preparation and crystallographic analysis of the free and epitope-complexed forms of its Fab′ fragment

被引:11
作者
Bryson, S
Cunningham, A
Ho, J
Hynes, RC
Isenman, DE
Barber, BH
Kunert, R
Katinger, H
Klein, M
Pai, EF
机构
[1] Univ Toronto, Ctr Excellence, Dept Biochem, Toronto, ON M5S 1A8, Canada
[2] Univ Toronto, Ctr Excellence, Dept Immunol, Toronto, ON M5S 1A8, Canada
[3] Univ Toronto, Ctr Excellence, Dept Med Biophys, Toronto, ON M5S 1A8, Canada
[4] Univ Toronto, Ctr Excellence, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada
[5] Univ Toronto, Ctr Excellence, Prot Engn Network, Toronto, ON M5S 1A8, Canada
[6] Princess Margaret Hosp, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada
[7] Agr Univ Vienna, Inst Appl Microbiol, A-1190 Vienna, Austria
[8] Aventis Pasteur, Res & Dev, F-69280 Marcy Letoile, France
关键词
D O I
10.2174/0929866013409201
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The human monoclonal antibody 2F5 is a potent neutralizer of most clades of HIV-1 and possesses protective effects against viral transmission. It recognizes the linear epitope ELDKWAS of the viral envelope protein gp41. As structural information about epitope recognition may help to develop an HIV-1 vaccine we initiated crystallographic analyses of mAb 2F5 and its epitope complex. We now report the preparation of the corresponding Fab' fragments, complexation with the epitope peptide, and crystallization of free mAb 2F5 Fab' as well as the peptide complex. Both crystal forms are well suited for high resolution structural analysis.
引用
收藏
页码:413 / 418
页数:6
相关论文
共 22 条
[11]   Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12 [J].
Mascola, JR ;
Louder, MK ;
VanCott, TC ;
Sapan, CV ;
Lambert, JS ;
Muenz, LR ;
Bunow, B ;
Birx, DL ;
Robb, ML .
JOURNAL OF VIROLOGY, 1997, 71 (10) :7198-7206
[12]   Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies [J].
Mascola, JR ;
Stiegler, G ;
VanCott, TC ;
Katinger, H ;
Carpenter, CB ;
Hanson, CE ;
Beary, H ;
Hayes, D ;
Frankel, SS ;
Birx, DL ;
Lewis, MG .
NATURE MEDICINE, 2000, 6 (02) :207-210
[13]   CROSS-NEUTRALIZING ACTIVITY AGAINST DIVERGENT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES INDUCED BY THE GP41 SEQUENCE ELDKWAS [J].
MUSTER, T ;
GUINEA, R ;
TRKOLA, A ;
PURTSCHER, M ;
KLIMA, A ;
STEINDL, F ;
PALESE, P ;
KATINGER, H .
JOURNAL OF VIROLOGY, 1994, 68 (06) :4031-4034
[14]   A CONSERVED NEUTRALIZING EPITOPE ON GP41 OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
MUSTER, T ;
STEINDL, F ;
PURTSCHER, M ;
TRKOLA, A ;
KLIMA, A ;
HIMMLER, G ;
RUKER, F ;
KATINGER, H .
JOURNAL OF VIROLOGY, 1993, 67 (11) :6642-6647
[15]   Processing of X-ray diffraction data collected in oscillation mode [J].
Otwinowski, Z ;
Minor, W .
MACROMOLECULAR CRYSTALLOGRAPHY, PT A, 1997, 276 :307-326
[16]   A BROADLY NEUTRALIZING HUMAN MONOCLONAL-ANTIBODY AGAINST GP41 OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
PURTSCHER, M ;
TRKOLA, A ;
GRUBER, G ;
BUCHACHER, A ;
PREDL, R ;
STEINDL, F ;
TAUER, C ;
BERGER, R ;
BARRETT, N ;
JUNGBAUER, A ;
KATINGER, H .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (12) :1651-1658
[17]   Restricted antigenic variability of the epitope recognized by the neutralizing gp41 ant body 2F5 [J].
Purtscher, M ;
Trkola, A ;
Grassauer, A ;
Schulz, PM ;
Klima, A ;
Dopper, S ;
Gruber, G ;
Buchacher, A ;
Muster, T ;
Katinger, H .
AIDS, 1996, 10 (06) :587-593
[18]   Atomic structure of a thermostable subdomain of HIV-1 gp41 [J].
Tan, KM ;
Liu, JH ;
Wang, JH ;
Shen, S ;
Lu, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (23) :12303-12308
[19]   CROSS-CLADE NEUTRALIZATION OF PRIMARY ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BY HUMAN MONOCLONAL-ANTIBODIES AND TETRAMERIC CD4-IGG [J].
TRKOLA, A ;
POMALES, AB ;
YUAN, H ;
KORBER, B ;
MADDON, PJ ;
ALLAWAY, GP ;
KATINGER, H ;
BARBAS, CF ;
BURTON, DR ;
HO, DD ;
MOORE, JP .
JOURNAL OF VIROLOGY, 1995, 69 (11) :6609-6617
[20]  
TURNER M W, 1970, Clinical and Experimental Immunology, V7, P603